Celularity (CELU) Minority Interest (2019 - 2020)
Celularity (CELU) posted quarterly Minority Interest of $209.1 million for Q4 2020, down 19.06% year-over-year from $258.4 million in Q1 2020, and down 24.34% quarter-over-quarter from $276.4 million in Q3 2020.
Celularity (CELU) Minority Interest (2019 - 2020) Analysis & Trends
Celularity (CELU) has reported Minority Interest for 2 consecutive years, with $209.1 million the latest figure, recorded in Q4 2020.
- In Q4 2020, Minority Interest fell 19.06% year-over-year to $209.1 million; the TTM figure through Dec 2020 stood at $209.1 million (down 19.06% YoY), while the FY2020 annual figure was $209.1 million, down 19.06% from the prior year.
- Minority Interest declined to $209.1 million in Q4 2020 per CELU's latest filing, from $276.4 million in the prior quarter.
- Across five years, Minority Interest topped out at $276.6 million in Q1 2020 and bottomed at $209.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - |
| 10 | Celularity | 20.73 Mn | 14.56 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 209.13 Mn |
| Sep 30, 2020 | 276.41 Mn |
| Jun 30, 2020 | 276.44 Mn |
| Mar 31, 2020 | 276.59 Mn |
| Dec 31, 2019 | 258.39 Mn |
| Sep 30, 2019 | 274.81 Mn |
| Jun 30, 2019 | 273.69 Mn |